136 / 1224
/
SBRT for stage I NSCLC
100%
All cancer
13%
(13%)
Lung cancer
10.4%
(80%)
NSCLC
2.1%
(20%)
Early stage NSCLC
0.23%
(11%)
Inoperable stage I NSCLC
Stage I NSCLC = RARE DISEASE
Majority of our patient will NOT benefit from SBRT
Proof of principle
ESTRO SBRT COURSE 2016 - Matthias Guckenberger
4